PMID- 33258536
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 34
IP  - 1
DP  - 2021 Jan
TI  - Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: 
      A systematic review and meta-analysis of randomized placebo-controlled trials.
PG  - e14609
LID - 10.1111/dth.14609 [doi]
AB  - To systematically and meta-analytically pool evidence from randomized 
      placebo-controlled trials that examined the efficacy and safety of topical 
      clascoterone cream in patients with acne vulgaris. Four databases were screened 
      from inception to 10 October 2020. Included studies were assessed for risk of 
      bias. Efficacy outcomes included investigator's global assessment (IGA) treatment 
      success and absolute change in inflammatory lesion counts (ILCs) and 
      noninflammatory lesion counts (NILCs). Safety outcomes included the proportion of 
      patients with any treatment-emergent adverse event (TEAE) as well as incidence of 
      any TEAE, serious adverse events (AEs), AEs related to study drug, AEs leading to 
      study drug discontinuation, nasopharyngitis, headache, oropharyngeal pain, and 
      vomiting. Dichotomous data were analyzed using the risk ratio (RR) and 95% 
      confidence interval (95% CI) whereas continuous data were analyzed using the mean 
      difference (MD) and 95% CI. Review Manager Software version 5.4.1 was used for 
      statistical analysis. Five clinical trials, comprising 2457 patients (1357 and 
      1100 patients received clascoterone and placebo, respectively) were included. 
      Studies revealed an overall low risk of bias. Clascoterone significantly 
      increased IGA success rates (RR = 2.87, 95% CI [2.11, 3.89], P < .001) and 
      decreased NILCs (MD = -5.64, 95% CI [-8.41, -2.87], P < .01) without 
      substantially impacting the ILCs (MD = -1.82, 95% CI [-5.06, 1.43], P = .27). No 
      significant differences were noted between both groups for all safety outcomes, 
      except for nasopharyngitis which was significantly lower in the clascoterone 
      group (RR = 0.47, 95% CI [0.27, 0.83], P = .01). Topical clascorterone cream is 
      safe and effective in the treatment of acne vulgaris.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Alkhodaidi, Shrooq Tail
AU  - Alkhodaidi ST
AD  - Department of Dermatology, King Abdulaziz Hospital, Makkah, Saudi Arabia.
FAU - Al Hawsawi, Khalid Ali
AU  - Al Hawsawi KA
AD  - Department of Dermatology, King Abdulaziz Hospital, Makkah, Saudi Arabia.
FAU - Alkhudaidi, Ishraq Tail
AU  - Alkhudaidi IT
AD  - College of Medicine, Taif University, Taif, Saudi Arabia.
FAU - Magzoub, Duha
AU  - Magzoub D
AD  - School of Public Health, The University of Memphis, Memphis, Tennessee, USA.
FAU - Abu-Zaid, Ahmed
AU  - Abu-Zaid A
AUID- ORCID: 0000-0003-2286-2181
AD  - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
AD  - Department of Pharmacology, College of Graduate Health Sciences, University of 
      Tennessee Health Science Center, Memphis, Tennessee, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201211
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Propionates)
RN  - WDT5SLP0HQ (Cortodoxone)
RN  - XN7MM8XG2M (Clascoterone)
SB  - IM
MH  - *Acne Vulgaris/diagnosis/drug therapy
MH  - Cortodoxone/analogs & derivatives
MH  - Humans
MH  - *Propionates
MH  - Randomized Controlled Trials as Topic
MH  - Skin Cream
OTO - NOTNLM
OT  - CB-03-01
OT  - Clascoterone
OT  - acne vulgaris
OT  - cortexolone 17alpha-propionate
EDAT- 2020/12/02 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/12/01 08:38
PHST- 2020/10/22 00:00 [received]
PHST- 2020/11/21 00:00 [accepted]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/12/01 08:38 [entrez]
AID - 10.1111/dth.14609 [doi]
PST - ppublish
SO  - Dermatol Ther. 2021 Jan;34(1):e14609. doi: 10.1111/dth.14609. Epub 2020 Dec 11.